Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1102 Topical Gel in Chronic Plaque Psoriasis
NCT06380907Phase 2Terminated
- Sponsor
- Zai Lab
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Fragments, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZL-1102 in plaque psoriasis (5 arms), sponsored by Zai Lab. Primary endpoint: Efficacy of different doses of ZL-1102 compared to Vehicle at 16 weeks. Started May 2024; status: terminated.
02
Drugs
ZL-1102
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06380907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380907.